MedTrace Logo

Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)

NCT07089303 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2025-08-14

No results posted yet for this study

Summary

This single-center prospective cohort study will enroll 750 participants (250 cognitively Normal (CN) individuals, 250 with mild cognitive impairment (MCI), and 250 with Alzheimer's disease (AD)). At baseline and at annual follow-ups, participants will undergo 3 Tesla (3 T) and 7 Tesla (7 T) multimodal magnetic resonance imaging (MRI) scans, blood biomarker testing, genotyping, and cognitive assessments to identify early imaging biomarkers and construct models of disease progression.

Conditions

  • Alzheimer Disease
  • Mild Cognitive Impairment Due to Alzheimer's Disease

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2029-07-31
Completion
2029-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07089303 on ClinicalTrials.gov